Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
AstraZeneca
McKesson
Medtronic
Johnson and Johnson

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Patent: 8,748,585

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,748,585
Title:Antibodies that bind to OX40 and their uses
Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
Inventor(s): Attinger; Antoine (La Chaux-de-Fonds, CH), Blein; Stanislas (La Chaux-de-Fonds, CH), Back; Jonathan Albert (La Chaux-de-Fonds, CH), Lissilaa; Rami (La Chaux-de-Fonds, CH), Hou; Samuel (La Chaux-de-Fonds, CH)
Assignee: Glenmark Pharmaceuticals S.A. (La Chaux-de-Fonds, CH)
Application Number:13/545,708
Patent Claims:see list of patent claims

Details for Patent 8,748,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Glenmark Pharmaceuticals S.A. (La Chaux-de-Fonds, CH) 2031-07-11 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Glenmark Pharmaceuticals S.A. (La Chaux-de-Fonds, CH) 2031-07-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Boehringer Ingelheim
Moodys
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.